GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » Short Interest

Bellicum Pharmaceuticals (FRA:BPXA) Short Interest


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Bellicum Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bellicum Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Short Interest falls into.


Bellicum Pharmaceuticals (FRA:BPXA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » Short Interest
Comparable Companies
HSTO GLMD NBY CYTO AGTX NTRR ISCO RUBY CFRX ADTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BLCM:USA
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Website
https://www.bellicum.com
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (FRA:BPXA) Headlines

No Headlines